Propranolol in Acute Migraine: A Controlled Study

Propranolol is an established agent in migraine prophylaxis. Uncontrolled studies have suggested an action in the acute attack. We present the first double-blind placebo controlled study of propranolol in 27 unselected patients with common (migraine without aura) and classical (migraine with aura) migraine. There were 23 pairs of headaches in the 14 patients who completed the study. No difference was found, when the data were analysed by headache pair or by patient, in severity duration and subjective assessment of efficacy between those treated in an attack with propranolol 40 mg and placebo.

Download Full-text

Intravenous Dipyrone in the Acute Treatment of Migraine Without Aura and Migraine with Aura: A Randomized, Double Blind, Placebo Controlled Study

Headache The Journal of Head and Face Pain ◽

10.1046/j.1526-4610.2002.02204.x ◽

2002 ◽

Vol 42 (9) ◽

pp. 862-871 ◽

Cited By ~ 33

Author(s):

Marcelo E. Bigal ◽

Carlos A. Bordini ◽

Stewart J. Tepper ◽

Jose G. Speciali

Keyword(s):

Migraine With Aura ◽

Acute Treatment ◽

Migraine Without Aura ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Intravenous Magnesium Sulphate in the Acute Treatment of Migraine Without Aura and Migraine with Aura. A Randomized, Double-Blind, Placebo-Controlled Study

Cephalalgia ◽

10.1046/j.1468-2982.2002.00364.x ◽

2002 ◽

Vol 22 (5) ◽

pp. 345-353 ◽

Cited By ~ 92

Author(s):

ME Bigal ◽

CA Bordini ◽

SJ Tepper ◽

JG Speciali

Keyword(s):

Migraine With Aura ◽

Magnesium Sulphate ◽

Acute Treatment ◽

Migraine Without Aura ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Significant Difference ◽

Therapeutic Gain ◽

Associated Symptoms

Magnesium sulphate has been used in the acute treatment of migraines; some studies found it to be a highly effective medication in the acute control of migraine pain and associated symptoms. This randomized, double-blind, placebo-controlled study assesses the effect of magnesium sulphate on the pain and associated symptoms in patients with migraine without aura and migraine with aura. Sixty patients in each group were assigned at random to receive magnesium sulphate, 1000 mg intravenously, or 0.9% physiological saline, 10 ml. We used seven parameters of analgesic evaluation and an analogue scale to assess nausea, photophobia and phonophobia. In the migraine without aura group there was no statistically significant difference in the patients who received magnesium sulphate vs. placebo in pain relief. The analgesic therapeutic gain was 17% and number needed to treat was 5.98 at 1 h. There was also no statistical difference in relief of nausea. We did observe a significant lower intensity of photophobia and phonophobia in patients who received magnesium sulphate. In the migraine with aura group patients receiving magnesium sulphate presented a statistically significant improvement of pain and of all associated symptoms compared with controls. The analgesic therapeutic gain was 36.7% at 1 h. A smaller number of patients continued to have aura in the magnesium sulphate group compared with placebo 1 h after the administration of medication. Our data support the idea that magnesium sulphate can be used for the treatment of all symptoms in migraine with aura, or as an adjuvant therapy for associated symptoms in patients with migraine without aura.

Download Full-text

Fenoprofen Calcium In Migraine Prophylaxis - A Double Blind, Placebo Controlled Study

Cephalalgia ◽

10.1177/03331024870070s6212 ◽

1987 ◽

Vol 7 (6_suppl) ◽

pp. 473-474

Author(s):

G.D. Solomon ◽

F.G. Freitag ◽

N. Mehta ◽

S. Diamond

Keyword(s):

Migraine Prophylaxis ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy of Phenazone in the Treatment of Acute Migraine Attacks: A Double-Blind, Placebo-Controlled, Randomized Study

Cephalalgia ◽

10.1111/j.1468-2982.2004.00764.x ◽

2004 ◽

Vol 24 (10) ◽

pp. 888-893 ◽

Cited By ~ 15

Author(s):

H Göbel ◽

A Heinze ◽

U Niederberger ◽

T Witt ◽

V Zumbroich

Keyword(s):

Adverse Events ◽

Randomized Study ◽

Controlled Study ◽

Acute Migraine ◽

Serious Adverse Events ◽

Double Blind ◽

Double Blind Placebo ◽

Number Of Patients ◽

Significant Difference ◽

Main Target

In this study we compared the efficacy of 1000 mg phenazone with that of placebo in the treatment of acute migraine attacks in a randomized double-blind, placebo-controlled study of 208 patients. The main target criterion was the number of patients with a pain reduction from severe or moderate to slight or no pain 2 h after taking the pain medication. The percentage of patients satisfying the main target criterion was 48.6% for phenazone and 27.2% ( P < 0.05) for placebo. Freedom from pain after 2 h was reported by 27.6% with phenazone treatment and 13.6% ( P < 0.05) with placebo. Compared with placebo, the phenazone treatment also resulted in a significant improvement in the associated migraine symptoms of nausea, phonophobia and photophobia. Of patients treated with phenazone 11.4%, and 5.8% of those treated with placebo reported adverse events. There was no significant difference between the groups with regard to numbers of patients with adverse events. No serious adverse events occurred. The results show that phenazone at a dosage of 1000 mg is effective and well tolerated in the treatment of acute migraine attacks.

Download Full-text

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

Cephalalgia ◽

10.1177/0333102418788347 ◽

2018 ◽

Vol 38 (10) ◽

pp. 1611-1621 ◽

Cited By ~ 44

Author(s):

Messoud Ashina ◽

Stewart Tepper ◽

Jan Lewis Brandes ◽

Uwe Reuter ◽

Guy Boudreau ◽

...

Keyword(s):

Chronic Migraine ◽

Preventive Treatment ◽

Controlled Study ◽

Acute Migraine ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Safety Issues ◽

Subgroup Analyses ◽

Specific Medication

Background Erenumab was effective and well tolerated in a pivotal clinical trial of chronic migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) versus placebo in the subgroup of patients who had previously failed preventive treatment(s) (≥ 1, ≥ 2 prior failed medication categories) and in patients who had never failed. Methods Subgroup analyses evaluated change from baseline in monthly migraine days; achievement of ≥ 50% and ≥ 75% reduction in monthly migraine days; and change in monthly acute migraine-specific medication days. Adverse events were evaluated for each subgroup. Results Treatment with both doses of erenumab resulted in greater reductions in monthly migraine days (primary endpoint) at Month 3 (treatment difference [95% CI], never failed subgroup: −2.2 [−4.1, −0.3] for 70 mg and −0.5 [−2.4, 1.5] for 140 mg; ≥ 1 prior failed medication categories subgroup: −2.5 [−3.8, −1.2], for 70 mg and −3.3 [−4.6, −2.1] for 140 mg; ≥ 2 prior failed medication categories subgroup: −2.7 [−4.2, −1.2], for 70 mg and −4.3 [−5.8, −2.8] for 140 mg). Similar results were observed in the monthly acute migraine-specific medication days endpoint, and in the achievement of ≥ 50% and ≥ 75% reduction in monthly migraine days. There were no new or unexpected safety issues. Conclusion Erenumab showed consistent efficacy in chronic migraine patients who had failed prior preventive treatments and was well tolerated across subgroups.

Download Full-text

A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents

PEDIATRICS ◽

10.1542/peds.106.5.989 ◽

2000 ◽

Vol 106 (5) ◽

pp. 989-997 ◽

Cited By ~ 159

Author(s):

Paul Winner ◽

A. David Rothner ◽

Joel Saper ◽

Robert Nett ◽

Mahnaz Asgharnejad ◽

...

Keyword(s):

Nasal Spray ◽

Controlled Study ◽

Acute Migraine ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Prophylactic Treatment of Migraine with Bisoprolol

Cephalalgia ◽

10.1046/j.1468-2982.1997.1705596.x ◽

1997 ◽

Vol 17 (5) ◽

pp. 596-599 ◽

Cited By ~ 29

Author(s):

LLM van de Ven ◽

CL Franke ◽

PJ Koehler

Keyword(s):

Prophylactic Treatment ◽

Placebo Treatment ◽

Migraine Prophylaxis ◽

Controlled Study ◽

Duration Of Treatment ◽

Double Blind ◽

Double Blind Placebo ◽

History Of

The objective of the present study was to assess the efficacy of bisoprolol in migraine prophylaxis. A double-blind placebo-controlled study was conducted in 226 patients with migraine with or without aura, a migraine history of at least 2 years and at least 3 documented attacks during the 28 days run-in period. The duration of treatment was 12 weeks following an initial 28 days' run-in period. Patients reported the number of attacks and their severity in a diary. Treatment with bisoprolol 5 mg resulted in a significant reduction in the frequency of migraine attacks (39% vs 22%) compared to placebo treatment ( p<0.05). Treatment had no effect on the duration and severity of the attacks. Bisoprolol was well tolerated.

Download Full-text

Comparison of Propranolol LA 80 mg and Propranolol LA 160 mg in Migraine Prophylaxis: A Placebo Controlled Study

Cephalalgia ◽

10.1046/j.1468-2982.1993.1302128.x ◽

1993 ◽

Vol 13 (2) ◽

pp. 128-131 ◽

Cited By ~ 15

Author(s):

Hisham K Al-Qassab ◽

Leslie J Findley

Keyword(s):

Side Effects ◽

Migraine Prophylaxis ◽

Controlled Study ◽

Headache Frequency ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo ◽

Headache Severity ◽

Negative Effect ◽

Long Acting

Thirty patients with severe classical and common migraine participated in a double-blind placebo-con-trolled cross-over study of migraine prophylaxis with propranolol LA (long-acting) 80 mg once daily, or propranolol LA 160 mg once daily or placebo. Each treatment was given for two months. There were no significant differences between the three treatment periods in headache frequency, headache severity, nausea frequency or severity. There was a non-significant trend for reduced duration of headache with the two doses of propranolol. The possible reasons for this negative effect are discussed. The safety of propranolol and its lack of serious side effects were demonstrated.

Download Full-text